2024
Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3Lymphoma
2022
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 285-308. PMID: 35276674, DOI: 10.6004/jnccn.2022.0015.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaAnaplastic large cell lymphomaLarge cell lymphomaAnaplastic lymphoma kinaseCell lymphomaLymphoma kinaseTreatment of PTCLNCCN Clinical Practice GuidelinesAngioimmunoblastic T-cell lymphomaClinical practice guidelinesNon-Hodgkin lymphomaMature T cellsNCCN guidelinesLymphoproliferative disordersCommon subtypePractice guidelinesT cellsLymphomaHeterogeneous groupGuidelinesSubtypesDiagnosisOncology
2015
The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project
Bellei M, Nabhan C, Pesce EA, Conte L, Vose JM, Foss F, Federico M. The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project. Current Hematologic Malignancy Reports 2015, 10: 448-455. PMID: 26449717, DOI: 10.1007/s11899-015-0291-0.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell ProjectLymphoma RegistryCell lymphomaManagement of PTCLFuture clinical trialsOptimal therapeutic strategyT-cell lymphomaB-cell lymphomaPoor prognosisLymphoma treatmentLarge registriesClinical trialsLymphoid malignanciesTherapeutic strategiesNew agentsRegistryHeterogeneous groupPrognosisLymphoma
2013
Treatment strategies for peripheral T-cell lymphomas
Foss FM. Treatment strategies for peripheral T-cell lymphomas. Best Practice & Research Clinical Haematology 2013, 26: 43-56. PMID: 23768640, DOI: 10.1016/j.beha.2013.04.005.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaAggressive first-line therapyAutologous stem cell transplantationConventional lymphoma therapyFirst-line therapyMajority of patientsStem cell transplantationSignal transduction inhibitorsHistone deacetylase inhibitorsFuture novel approachesLine therapyTransplant candidatesImproved survivalRelevant pathwaysAggressive diseaseCell transplantationInferior outcomesLymphoma therapyTransduction inhibitorsTreatment strategiesDeacetylase inhibitorsMonoclonal antibodiesMolecular profilingHeterogeneous group
2011
Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond
Foss F. Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond. Therapeutic Advances In Hematology 2011, 2: 161-173. PMID: 23556087, PMCID: PMC3573405, DOI: 10.1177/2040620711408491.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaT-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaFirst-line therapySubset of patientsAggressive clinical courseNon-Hodgkin lymphomaB-cell lymphomaHistone deacetylase inhibitorsCurative optionRefractory diseaseClinical courseCell transplantationTherapeutic advancesNew agentsTreatment approachesLymphomaDeacetylase inhibitorsMonoclonal antibodiesHeterogeneous groupProteasome inhibitorsNucleoside analoguesPatientsTherapyPeripheral T-cell lymphoma
Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood 2011, 117: 6756-6767. PMID: 21493798, DOI: 10.1182/blood-2010-05-231548.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaStandard chemotherapeutic regimensBest treatment strategyMore effective therapiesHistone deacetylase inhibitorsWorld Health OrganizationAbundance of drugsAggressive diseaseChemotherapeutic regimensPoor outcomeTreatment optionsClinical trialsEffective therapyTreatment strategiesTherapeutic approachesPrognostic issuesDeacetylase inhibitorsLymphoma classificationMonoclonal antibodiesGene expression profilingHeterogeneous groupHealth OrganizationProteasome inhibitorsDisease biologyMolecular Predictors of Response in Aggressive T-cell Lymphomas
Foss FM. Molecular Predictors of Response in Aggressive T-cell Lymphomas. The Cancer Journal 2011, 17: 142-148. PMID: 21427558, DOI: 10.1097/ppo.0b013e31821828b7.Peer-Reviewed Original ResearchConceptsAggressive T-cell lymphomaT-cell lymphomaNatural killer cellsNon-Hodgkin lymphomaWorld Health OrganizationKiller cellsInferior outcomesPrognostic characterizationMore accurate diagnosisTreatment strategiesMolecular predictorsTherapeutic strategiesAccurate diagnosisDistinct entityLymphomaGene expression profilingHealth OrganizationHeterogeneous groupRecent dataMolecular featuresDevelopment of novelExpression profilingMolecular analysisRegimensMalignancy
2010
Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.
Armitage JO, Hsi ED, Foss FM. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clinical Advances In Hematology And Oncology 2010, 8: 1-15. PMID: 21491667.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaPTCL subtypesTherapeutic regimensDisease state awarenessAggressive disease courseT-cell markersB-cell lymphomaMost patientsRefractory diseaseDisease courseIndolent courseAggressive diseaseLymphoproliferative disordersPoor prognosisTherapeutic overviewEffective treatmentProper diagnosisLymphomaRegimensSubtypesHeterogeneous groupPatientsPrognosisDisease
2008
Cutaneous T-cell Lymphoma
Lansigan F, Choi J, Foss FM. Cutaneous T-cell Lymphoma. Hematology/Oncology Clinics Of North America 2008, 22: 979-996. PMID: 18954747, DOI: 10.1016/j.hoc.2008.07.014.Peer-Reviewed Original Research